BALTIMORE, MD--(Marketwired - May 10, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that according to a recent article in the highly regarded bioscience publication BioSpectrum Asia, Nuvilex Inc. (OTCQB: NVLX) affiliate Austrianova Singapore has taken steps vital to the Company's goal of engaging in late-stage pancreatic cancer clinical trials. Nuvilex is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.
The Firm has established a research cell bank in concert with a leading contract research organization in Europe. This cell bank will be used for the production of the Company's live cell encapsulation offering, which has demonstrated significant ability to activate the cancer pro-drug ifosfamide in close proximity to the pancreatic cancer itself, thus resulting in a high degree of antitumor efficacy with a low toxicity profile for the anticancer drug, in Phase II clinical trials.
Given that a Phase III pancreatic cancer trial or trials to treat other forms of cancer would require a large number of cells due to number of study subjects, Nuvilex (OTCQB: NVLX) stands prepared to produce the requisite number of cells necessary for such trials.
The remarkable performance of the Company's encapsulated cell technology platform for pancreatic cancer has been cited in a number of medical journals and publications including the highly regarded Lancet and Cancer Therapy. Plus, data from the aforementioned pancreatic trial studies was recently featured in a review of promising cancer therapies by leading international scientists from the International Society for Cell and Gene Therapy.
Validation from these well-regarded third-party sources and the launch of the cell bank indicate that Nuvilex (OTCQB: NVLX) is on the cusp of making significant progress toward the initiation of various cancer clinical trials, most importantly the late-stage pancreatic cancer trial, given the devastating and deadly nature of that disease.
To view a summary of Nuvilex reports or download the reports in their entirety, please visit www.goldmanresearch.com
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.